Living with chronic inflammatory diseases extends far beyond managing physical symptoms. These conditions impose a profound and lasting burden on patients’ lives as recurring flares contribute to significant psychological distress and social stigma.

Although advances in targeted therapies have improved outcomes for many patients, achieving and maintaining disease control remains elusive across multiple chronic indications due to an efficacy ceiling and loss of response, which limit long-term benefit.

The next major advance is expected to come from therapeutics capable of modulating multiple validated inflammatory pathways simultaneously, ideally delivered in a safe, well tolerated and convenient oral form to support sustained adherence.